Ref |
n total (R/C) |
Rate of nausea and/or vomiting* n |
Willingness to repeat, n |
Recall n |
Satisfaction
with sedation Pain, working
conditions, comfort. |
||||||||||
Author/physician
favours |
Patient
Favours |
||||||||||||||
|
|
R |
C |
P-value |
R |
C |
R |
C |
R |
C |
No diff. |
R |
C |
No diff. |
|
Remifentanil vs. Propofol |
|||||||||||||||
Lee et al. [17] |
50 (25/32) |
NA |
NA |
|
NA |
NA |
NA |
NA |
NA |
NA |
|
NA |
NA |
|
|
Bouvet et al. [19] |
77 (41/36) |
14 |
0 |
ns |
NA |
NA |
NA |
NA |
|
|
X |
|
|
x |
|
Krenn et al. [20] |
60 (30/30) |
NA |
NA |
|
NA |
NA |
NA |
NA |
NA |
NA |
|
|
|
x |
|
Holas et al. [22] |
30 (15/15) |
4 |
0 |
<0.027 |
NA |
NA |
NA |
NA |
|
|
X |
|
|
x |
|
Lena et al. [26] |
40 (20/20) |
2 |
0 |
ns |
NA |
NA |
NA |
NA |
|
|
X |
|
|
x |
|
Zhang et al. [29] |
36 (18/18) |
NA |
NA |
|
18 |
17 |
18 |
7 |
X |
|
|
|
|
x |
|
Lallo et al. [30] |
60 (30/30) |
0 |
0 |
ns |
NA |
NA |
26 |
14 |
X |
|
|
|
|
x |
|
Ferraro et al. [31] |
60 (30/30) |
5 |
3 |
ns |
NA |
NA |
NA |
NA |
X |
|
|
NA |
NA |
|
|
Girard et al. [34] |
40 (20/20) |
NA |
NA |
|
NA |
NA |
NA |
NA |
NA |
NA |
|
NA |
NA |
|
|
Sub Total, n |
460 (229/231) |
25/136 |
3/131 |
<0.005 |
18/18 |
17/17 |
44/45 |
38/45 |
3/6 |
0/6 |
3/6 |
0/6 |
0/6 |
6/6 |
|
% |
|
18.4 |
2.3 |
|
100 |
100 |
98 |
47 |
|
|
|
|
|
|
|
Remifentanil vs. Midazolam + opioid |
|||||||||||||||
Avramov et al. [3] |
81 (19/62) |
10 |
21 |
ns |
17 |
56 |
19 |
24 |
NA |
NA |
|
|
|
X |
|
Bonfreschi et al. [16] |
50(25/25) |
0 |
0 |
ns |
NA |
NA |
NA |
NA |
X |
|
|
NA |
NA |
|
|
Fanti et al. [18] |
90 (60/30) |
0 |
4 |
0.032 |
57 |
30 |
59 |
30 |
|
|
X |
|
|
X |
|
Lier et al. [23] |
78 (38/40) |
NA |
NA |
|
NA |
NA |
NA |
NA |
NA |
NA |
|
X |
|
|
|
Puchner et al. [24] |
74 (37/37) |
NA |
NA |
|
NA |
NA |
6 |
0 |
X |
|
|
|
|
X |
|
Manolaraki et al. [25] |
116 (60/56) |
2 |
3 |
ns |
60 |
56 |
NA |
NA |
|
|
X |
|
|
X |
|
Ferraro et al. [31] |
60 (30/30) |
7 |
6 |
ns |
NA |
NA |
NA |
NA |
X |
|
|
NA |
NA |
|
|
Sub Total, n |
549 (269/280) |
19/172 |
34/187 |
<0.005 |
134/139 |
142/148 |
84/116 |
54/129 |
3/5 |
0/5 |
2/5 |
1/5 |
0/5 |
4/5 |
|
% |
|
9.8 |
16.7 |
|
96 |
96 |
72 |
42 |
|
|
|
|
|
|
|
Remifentanil vs. opioid |
|||||||||||||||
Orbach-zinger
et al. [12] |
30 (14/16) |
6 |
3 |
ns |
NA |
NA |
NA |
NA |
|
|
X |
|
|
X |
|
Cortinez et al. [27] |
44 (22/22) |
3 |
9 |
ns |
NA |
NA |
NA |
NA |
NA |
NA |
|
NA |
NA |
|
|
Akgül
et al. [35] |
80 (40/40) |
NA |
NA |
|
NA |
NA |
NA |
NA |
|
|
X |
|
|
X |
|
Sub Total, n |
154 (76/78) |
9/36 |
12/38 |
0.611 |
|
|
|
|
0/2 |
0/2 |
2/2 |
0/2 |
0/2 |
2/2 |
|
% |
|
25.0 |
31.6 |
|
|
|
|
|
|
|
|
|
|
|
|
Remifentanil vs. Propofol + Remifentanil |
|||||||||||||||
Joo et al. [13] |
120 (60/60) |
16 |
5 |
0.016 |
51 |
53 |
NA |
NA |
|
|
X |
|
X |
|
|
Holas et al. [22] |
30 (15/15) |
4 |
0 |
<0.027 |
NA |
NA |
NA |
NA |
|
X |
|
|
|
X |
|
Sub Total, n |
150 (75/75) |
20/75 |
5/75 |
0.002 |
51/60 |
53/60 |
|
|
0/2 |
1/2 |
1/2 |
0/2 |
1/2 |
1/2 |
|
% |
|
26.7 |
6.7 |
|
85 |
88 |
|
|
|
|
|
|
|
|
|
Remifentanil vs. TIVA: Propofol+Remifentanil |
|||||||||||||||
Majholm et al.[15] |
91
(49/42) |
11 |
2 |
0.016 |
45 |
27 |
NA |
NA |
|
|
X |
X |
|
|
|
% |
|
22.4 |
4.8 |
|
92 |
65 |
|
|
|
|
|
|
|
|
|
Remifentanil
vs. Dexmedetomidine |
|||||||||||||||
Hu et al. [14] |
40
(20/20) |
NA |
NA |
|
NA |
NA |
13 |
6 |
|
X |
|
|
X |
|
|
Total, n |
1444 (718/726) |
84/490 |
56/489 |
p=0.013 |
248/266 |
239/267 |
141/181 |
98/194 |
6/17 |
2/17 |
9/17 |
2/17 |
2/17 |
13/17 |
|
% |
|
16.5 |
10.2 |
|
93.2 |
89.5 |
77.9 |
50.5 |
35.2 |
11.8 |
53.0 |
11.8 |
11.8 |
76.5 |
|
Table
3: Postoperative nausea and vomiting and satisfaction